Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy

American Journal of Health-System Pharmacy

Volumn 61, Issue 23, 2004, Pages 2507-2522

  Schiller, Daryl S ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Antiretroviral agents; Clinical pharmacists; Compliance; HIV infections; Interventions; Patient information; Patients; Pharmacoeconomics; Quality of life; Resistance; Toxicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; BISMUTH SALICYLATE; BISPHOSPHONIC ACID DERIVATIVE; CROFELEMER; DIDANOSINE; DRONABINOL; EFAVIRENZ; ERYTHROPOIETIN; FIBRIC ACID DERIVATIVE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; LAMOTRIGINE; LORAZEPAM; MEGESTROL ACETATE; METFORMIN; METOCLOPRAMIDE; PANCRELIPASE; PRAVASTATIN; PROCHLORPERAZINE; PROSTAGLANDIN E1; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; STAVUDINE; ULTRASE MT20; UNINDEXED DRUG; ZOLPIDEM;

ACUTE PANCREATITIS; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ATHEROSCLEROSIS; AVASCULAR NECROSIS; BONE DEMINERALIZATION; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DREAMING; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRY SKIN; EOSINOPHILIA; ERECTILE DYSFUNCTION; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FATTY LIVER; FLUSHING; GRANULOMA; HEALTH CARE COST; HEART INFARCTION; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPOTENSION; INGROWN NAIL; INJECTION SITE; KIDNEY DISEASE; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MENTAL STRESS; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MORBIDITY; MUSCLE DISEASE; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SKIN MANIFESTATION; SLEEP DISORDER; TOXIC HEPATITIS; TREATMENT FAILURE; UROLITHIASIS; VOMITING; ANTIBIOTIC RESISTANCE; COST; DRUG EFFECT; DRUG INFORMATION; DRUG MONITORING; ECONOMICS; METHODOLOGY; PHARMACIST; PROFESSIONAL STANDARD; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSTS AND COST ANALYSIS; DRUG INFORMATION SERVICES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACISTS; PROFESSIONAL ROLE; QUALITY OF LIFE;

EID: 15544385601     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.23.2507     Document Type: Review

References (175)

1. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
2. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001; 358:1322-7.
3. Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. AIDS. 2002; 16:737-45.
4. O'Brien ME, Clark RA, Besch CL et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003; 34:407-14.
5. Goldie SJ, Paltiel AD, Weinstein MC et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003; 115:632-41.
6. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. Pharmacoeconomics. 1996; 10:109-13.
7. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002; 24:1502-14.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 10, 2003:15,18, 20,24-29,33,34,60,65.
9. Beal J, Flynn N. AIDS-associated anorexia. J Physicians Assoc AIDS Care. 1995; 2:19-22.
10. Bartlett JG, Gallant JE. 2003 Medical management of HIV infection. Baltimore: Johns Hopkins University; 2003:82-89,344,345.
11. 3. Am J Gastroenterol. 2000; 95:3142-6.
12. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000; 30:908-14.
13. Weber R, Ledergerber B, Zbinden R et al. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Arch Intern Med. 1999; 159:1473-80.
14. Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS. 2003; 17(suppl 1):S51-64.
15. Oldfield EC III. Evaluation of chronic diarrhea in patients with human immunodeficiency virus infection. Rev Gastroenterol Disord. 2002; 2:176-88.
16. Poles MA, Fuerst M, McGowan I et al. HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. Am J Gastroenterol. 2001; 96:1831-7.
17. Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med. 2004; 350:38-47.
18. Kunches LM, Reinhalter NE, Marquis A et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr. 2001; 28:150-3.
19. Viracept (nelfinavir mesylate) package insert. La Jolla, CA: Agouron Pharmaceuticals; 2003 Apr.
20. Huffman FG, Walgren ME. L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals. HIV Clin Trials. 2003; 4:324-9.
21. Guerrant RL, Van Gilder T, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001; 32:331-51.
22. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med. 1999; 107:78-84.
23. Havlir DV, Gilbert PB, Bennett K et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS. 2001; 15:1379-88.
24. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001; 15:617-20.
25. Barreiro P, de Mendoza C, Camino N et al. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. HIV Clin Trials. 2003; 4:361-71.
26. Lisziewicz J, Foli A, Wainberg, M et al. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf. 2003; 26:605-24.
27. Berardi RR, Montgomery PA. Pancreatitis. In: Dipiro JT, Talbert RL, Yee GC et al, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. Burr Ridge, IL: McGraw-Hill Medical Publishing Division; 2002:701-15.
28. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001; 15:1261-8.
29. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283:74-80.
30. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS. 1998; 12:2289-93.
31. Montaner JS, Cote HC, Harris M et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 34(suppl 1):S85-90.
32. De Maat MM, ter Heine R, van Gorp EC et al. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS. 2003; 17:2209-14.
33. Shepard KV, Boehringer Ingelheim Pharmaceuticals, Inc. "Dear healthcare professional" letter, www.biodocs.com/renetnt:/Notifications/ Dear+HCP +ltr+Feb+2004.pdf (accessed 2004 Feb 20).
34. Dore G. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. J HIV Ther. 2003; 8:96-100.
35. Romero M, Perez-Olmeda M, Garcia-Samaniego J et al. Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf. 2004; 27:7-24.
36. Wit FW, Weverling GJ, Weel J et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002; 186:23-31.
37. Carr A, Emery S, Law M et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 361:726-35.
38. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003; 17(suppl 1):S141-8.
39. Behrens GM, Meyer-Olson D, Stoll M et al. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS. 2003; 17(suppl 1):S149-54.
40. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis. 2003; 37(suppl 2):S85-90.
41. Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003; 37:613-27.
42. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001; 104:257-62.
43. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999; 100:700-5.
44. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003; 17(suppl 1):S162-9.
45. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002; 360:1747-8.
46. Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003; 4:1-10.
47. Rhew DC, Bernal M, Aguilar D et al. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis. 2003; 37:959-72.
48. Smith CJ, Levy I, Sabin CA et al. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med. 2004; 5:88-92.
49. Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000; 14:F123-8.
50. Seminari E, Pan A, Voltini G et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002; 162:433-8.
51. De Gaetano Donati K, Rabagliati R, Iacoviello L et al. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis. 2004; 4:213-22.
52. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004; 109:1603-8.
53. Maggi P, Lillo A, Perilli F et al. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS. 2004; 18:1023-8.
54. Feldman JG, Goldwasser P, Holman S et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003; 32:210-4.
55. Koppel K, Bratt G, Schulman S et al. Hypofibrinolvtic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 29:441-9.
56. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-421.
57. Moyle GJ, Lloyd M, Reynolds B et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001; 15:1503-8.
58. Stein JH, Merwood MA, Bellehumeur JL et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004; 147:713.
59. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002; 42:963-70.
60. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003; 17:851-9.
61. Badiou S, Merle De Boever C, Dupuy AM et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004; 172:273-9.
62. Miller J, Brown D, Amin J et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002; 16:2195-200.
63. Negredo E, Ribalta J, Paredes R et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002; 16:1383-9.
64. Van der Valk M, Kastelein JJ, Murphy RL et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001; 15:2407-14.
65. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003; 32:18-29.
66. Lichtenstein KA, Ward DJ, Moorman AC et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001; 15:1389-98.
67. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001; 15:1811-22.
68. John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003; 33:29-33.
69. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002; 288:207-15.
70. Moyle GJ, Baldwin C, Langroudi B et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003; 33:22-8.
71. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003; 349:1036-46.
72. Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis. 2003; 37(suppl 2):S142-9.
73. Kotler DP, Muurahainen N, Grunfeld C et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004; 35:239-52.
74. Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000; 284:472-7.
75. Gelato MC, Mynarcik DC, Quick JL et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002; 31:163-70.
76. Calmy A, Hirschel B, Hans D et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS. 2003; 17:770-2.
77. Lafaurie M, Dolivo M, Boulu D et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 mon.
78. Gervasoni C, Vaccarezza M, Fedeli P et al. Long-term efficacy of buffalo hump surgical treatment in patients continuing antiretroviral therapy. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
79. Bonnet F, Bonarek M, Morlat P et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis. 2003; 36:1324-8.
80. Marceau G, Sapin V, Jacomet C et al. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive persons: implications for the management of treated patients. Clin Chem. 2003; 49:1154-62.
81. Brinkman K, ter Hofstede HJ, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12:1735-44.
82. Carr A, Miller J, Eisman JA et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001; 15:703-9.
83. Boubaker K, Flepp M, Sudre P et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001; 33:1931-7.
84. Falco V, Rodriguez D, Ribera E et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002; 34:838-46.
85. Warning for pregnant women on HIV therapy. FDA Consum. 2001; 35:5. News.
86. John M, Moore CB, James IR et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001; 15:717-23.
87. Manfredi R, Motta R, Patrono D et al. Frequency, risk factors and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy. AIDS. 2003; 17:2131-3.
88. Carr A, Miller J, Law M et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000; 14:F25-32.
89. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001; 15:795-7.
90. Bruera D, Luna N, David DO et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17: 1917-23.
91. Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000; 14:F63-7.
92. Vigano A, Zamproni I, Giacomet V et al. Analysis of bone mineral content in antiretroviral-naive and highly active antiretroviral-treated HIV-infected children. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
93. Miller RF, Shahmonesh M, Hanna MG et al. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. Antivir Ther. 2003; 8:253-7.
94. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(suppl 2):S101-5.
95. Brown TT, Ruppe MD, Kassner R et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004; 89:1200-6.
96. McCromsey G, Huang J, Woolley I et al. Fragility fractures in HIV-infected subjects: an area for improvement. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
97. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002; 31:257-75.
98. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001; 6:21-7.
99. Brambilla AM, Vigano MG, Bossolasco S et al. HAART-induced immune reconstitution-associated lesions of the central nervous system. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
100. Blanch J, Martinez E, Rousaud A et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001; 27:336-43.
101. Gallego L, Barreiro P, del Rio R et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis. 2004; 38:430-2.
102. Lochet P, Peyriere H, Lotthe A et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003; 4:62-6.
103. Nunez M, Gonzalez de Requena D, Gallego L et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr. 2001; 28:399-400. Letter.
104. Von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001; 41:85-91.
105. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr. 2000; 24:129-36.
106. Harrison MJ. Guidelines for management of HIV-associated dementia, myelopathy, neuropathy and myopathy. Int J STD AIDS. 1998; 9:390-3.
107. Schifitto G, McDermott MP, McArthur JC et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology. 2002; 58:1764-8.
108. Simpson DM, McArthur JC, Olney R et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003; 60:1508-14.
109. Moore RD, Wong WM, Keruly JC et al. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS. 2000; 14:273-8.
110. Newshan G. HIV neuropathy treated with gabapentin. AIDS. 1998; 12:219-21.
111. Kieburtz K, Simpson D, Yiannoutsos C et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998; 51:1682-8.
112. HIV neuropathy. Proj Inf Perspect. 1997:12-3.
113. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med. 2003; 139:214-26.
114. Lucas GM, Eustace JA, Mentari EK et al. The effect of antiretroviral therapy on the incidence of HIV-associated nephropathy: a 12-year urban cohort study. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
115. Saltel E, Angel JB, Futter NG et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000; 164:1895-7.
116. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002; 40:1331-3.
117. Nadler RB, Rubenstein JN, Eggener SE et al. The etiology of urolithiasis in HIV infected patients. J Urol. 2003; 169:475-7.
118. Daudon M, Estepa L, Viard JP et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997; 349:1294-5. Letter.
119. Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000; 10:557-61.
120. Famularo G, Di Toro S, Moretti S et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother. 2000; 34:1414-8.
121. Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol. 1999; 13:309-12.
122. De Araujo M, Seguro AC. Vasodilator agents protect against indinavir nephrotoxicity. Antivir Ther. 2003; 8:295-9.
123. Grases F, Costa-Bauza A, Garcia-Gonzalez R et al. Indinavir crystallization and urolithiasis. Int Urol Nephrol. 1999; 31:23-9.
124. Reynes J, Peyriere H, Merle de Boever C et al. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
125. Rollot F, Nazal EM, Chauvelot-Moachon L et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003; 37:e174-6.
126. Creput C, Gonzalez-Canali G, Hill G. et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003; 17:935-7.
127. Schaaf B, Aries SP, Kramme E et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003; 37:e41-3.
128. Parish MA, Gallant JE, Moore RD. Changes in renal function in patients treated with tenofovir DF vs nucleoside reverse transcriptase inhibitors. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
129. Harris M, Zalunardo N, Bonner S et al. Use of estimated glomerular filtration rate to predict renal toxicity in patients receiving tenofovir DF. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
130. Cihlar T, Ho ES, Lin DC et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001; 20:641-8.
131. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001; 299:567-74.
132. Gutmann H, Fricker G, Drewe J et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999; 56:383-9.
133. Maurer T, Rodrigues LK, Ameli N et al. The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women. Clin Infect Dis. 2004; 38:579-84.
134. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000; 356:1423-30.
135. Floridia M, Bucciardini R, Fragola V et al. Risk factors and occurrence of rash in HIV-positive patients not receiving non-nucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). HIV Med. 2004; 5:1-10.
136. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003; 11:55-9.
137. Bouscarat F, Prevot MH, Matheron S. Alopecia associated with indinavir therapy. N Engl J Med. 1999; 341:618. Letter.
138. D'Arminio Monforte A, Testa L, Gianotto M et al. Indinavir-related alopecia. AIDS. 1998; 12:328. Letter.
139. James CW, McNelis KC, Cohen DM et al. Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy. Ann Pharmacother. 2001; 35:881-4.
140. Wasmuth JC, la Porte CJ, Schneider K et al. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther. 2004; 9:213-20.
141. Ball RA, Kinchelow T. Pathology of injection site reactions with enfuvirtide. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
142. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1:305-10.
143. Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1:311-6.
144. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359:727-32.
145. Martin AM, Almeida CA, Nolan D et al. Carriage of HLA-B*5701 and a haplotypic Hsp70-Hom variant is associated with a class I MHC-restricted hypersensitivity response to abacavir. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
146. Barreiro P, Soriano V, Gonzalez-Lahoz J. Prevention of nevirapine-associated rash. Lancet. 2001; 357:392. Letter.
147. Bourezane Y, Salard D, Hoen B et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis. 1998; 27:1321-2.
148. Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia. 1999; 5:266-9.
149. Sullivan PS, Hanson DL, Chu SY et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998; 91:301-8.
150. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol. 1997; 75:179-87.
151. Levine AM, Berhane K, Masri-Lavine L et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001; 26:28-35.
152. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS. 1999; 13:943-50.
153. Volberding P. Consensus statement: anemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther. 2000; 22:1004-20.
154. Grossman HA, Goon B, Bowers P et al. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. J Acquir Immune Defic Syndr. 2003; 34:368-78.
155. Collazos J, Martinez E, Mayo J et al. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31:322-6.
156. Lallemand F, Salhi Y, Linard F et al. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr. 2002; 30:187-90.
157. Schrooten W, Colebunders R, Youle M et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001; 15:1019-23.
158. Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy. Lancet. 1999; 353:840. Letter.
159. Merry C, Barry MG, Ryan M et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999; 13:F101-7.
160. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001; 344:472-80.
161. Binley JM, Schiller DS, Ortiz GM et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000; 181:1249-63.
162. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000; 407:523-6.
163. Kaufmann D, Lichterfeld M, Altfeld M et al. Limited durability of immune control following treated acute HIV infection. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 Feb.
164. Hatano H, Miller KD, Yoder CP et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 2000; 14:1935-42.
165. Tremblay CL, Hicks JL, Sutton L et al. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS. 2003; 17:1086-9.
166. Fagard C, Le Braz M, Gunthard H et al. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. AIDS. 2003; 17:1487-92.
167. Garcia F, Plana M, Arnedo M et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003; 17:43-51.
168. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis. 2002; 15:17-22.
169. Pellegrin I, Breilh D, Birac V et al. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. Ther Drug Monit 2001; 23:332-40.
170. De Maat MM, Huitema AD, Mulder JW et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003; 25:367-73.
171. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15:71-5.
172. Burger DM, Hugen PW, Aarnoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003; 25:73-80.
173. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999; 13:473-8.
174. Geletko SM, Poulakos MN. Pharmaceutical services in an HIV clinic. Am J Health-Syst Pharm. 2002; 59:709-13.
175. Cantwell-McNelis K, James CW. Role of clinical pharmacists in outpatient HIV clinics. Am J Health-Syst Pharm. 2002; 59:447-52.